# Tyra Biosciences Inc. (TYRA)

Source: https://www.quantisnow.com/company/TYRA
Generated: 2026-11-08T19:58:05.991Z

- Ticker: TYRA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- SEC CIK: 0001863127
- Website: tyra.bio

## About

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

## Latest TYRA news and filings

- 2026-11-05 21:05 UTC [Conference Announcement] [Tyra Biosciences to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/tyra-biosciences-to-participate-in-upcoming-investor-conferences-6776083)
- 2026-09-21 21:21 UTC [SEC Form SCHEDULE 13G filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-tyra-biosciences-inc-6721991)
- 2026-09-17 23:29 UTC [SEC Form 4] [President and CEO Harris Todd was granted 864 shares, increasing direct ownership by 0.06% to 1,438,495 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-harris-todd-was-granted-864-shares-increasing-6719809)
- 2026-09-17 23:26 UTC [SEC Form 4] [Vice President, Finance (PAO) Rueb Yuliya was granted 2,925 shares, increasing direct ownership by 35% to 11,258 units (SEC Form 4)](https://www.quantisnow.com/insight/vice-president-finance-pao-rueb-yuliya-was-granted-2925-shares-6719808)
- 2026-09-17 23:25 UTC [SEC Form 4] [Chief Financial Officer Fuhrman Alan was granted 951 shares, increasing direct ownership by 3% to 37,115 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-fuhrman-alan-was-granted-951-shares-increasing-6719807)
- 2026-09-17 20:32 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-tyra-biosciences-inc-6719391)
- 2026-09-17 20:31 UTC [SEC Form 4] [SEC Form 4 filed by Director Ra Capital Management, L.P.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ra-capital-management-lp-6719380)
- 2026-09-17 20:06 UTC [SEC Form SCHEDULE 13G filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-tyra-biosciences-inc-6719091)
- 2026-09-14 23:09 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-tyra-biosciences-inc-6715219)
- 2026-09-14 23:12 UTC [SEC Form 8-K] [SEC Form 8-K filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-tyra-biosciences-inc-6715218)
- 2026-09-14 10:45 UTC [Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants](https://www.quantisnow.com/insight/tyra-announces-pricing-of-400-million-underwritten-offering-of-common-6713621)
- 2026-09-14 10:33 UTC [SEC Form FWP] [SEC Form FWP filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-fwp-filed-by-tyra-biosciences-inc-6713609)
- 2026-09-14 10:02 UTC [SEC Form S-3ASR] [SEC Form S-3ASR filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-3asr-filed-by-tyra-biosciences-inc-6713566)
- 2026-09-11 20:30 UTC [Insider Buy] [Director Verjee Rehan bought $20,000 worth of shares (972 units at $20.58) (SEC Form 4)](https://www.quantisnow.com/insight/director-verjee-rehan-bought-20000-worth-of-shares-972-units-6713127)
- 2026-09-09 11:10 UTC [SEC Form 8-K] [SEC Form 8-K filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-tyra-biosciences-inc-6709202)
- 2026-09-09 11:00 UTC [Earnings Date] [Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib](https://www.quantisnow.com/insight/tyra-biosciences-reports-initial-phase-2-surf302-results-supporting-the-6709176)
- 2026-09-08 20:05 UTC [Conference Announcement] [Tyra Biosciences to Present at the Cantor Global Healthcare Conference](https://www.quantisnow.com/insight/tyra-biosciences-to-present-at-the-cantor-global-healthcare-conference-6708220)
- 2026-09-04 12:00 UTC [Earnings Date] [Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026](https://www.quantisnow.com/insight/tyra-biosciences-to-host-conference-call-on-initial-results-of-6706254)
- 2026-08-14 20:44 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-tyra-biosciences-inc-6683442)
- 2026-08-14 12:24 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-tyra-biosciences-inc-6681963)
- 2026-08-04 20:59 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-tyra-biosciences-inc-6662897)
- 2026-08-04 20:42 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-tyra-biosciences-inc-6662766)
- 2026-08-04 20:05 UTC [Earnings Date] [Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights](https://www.quantisnow.com/insight/tyra-biosciences-reports-second-quarter-2026-financial-results-and-recent-6662030)
- 2026-08-04 20:04 UTC [SEC Form 8-K] [Tyra Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/tyra-biosciences-inc-filed-sec-form-8-k-results-of-operations-6662020)
- 2026-06-26 20:59 UTC [SEC Form 144] [SEC Form 144 filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-tyra-biosciences-inc-6617679)
- 2026-06-02 20:01 UTC [SEC Form 8-K] [SEC Form 8-K filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-tyra-biosciences-inc-6584002)
- 2026-06-01 21:45 UTC [SEC Form 4] [SEC Form 4 filed by Director Ra Capital Management, L.P.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ra-capital-management-lp-6582523)
- 2026-06-01 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Simson Jake](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-simson-jake-6581983)
- 2026-06-01 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Moran Susan](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-moran-susan-6581982)
- 2026-06-01 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Verjee Rehan](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-verjee-rehan-6581978)
- 2026-06-01 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Gulfo Adele M.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-gulfo-adele-m-6581976)
- 2026-06-01 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Rothenberg Stephen Michael](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-rothenberg-stephen-michael-6581968)
- 2026-06-01 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director More Robert J](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-more-robert-j-6581967)
- 2026-06-01 20:16 UTC [SEC Form 144] [SEC Form 144 filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-tyra-biosciences-inc-6581820)
- 2026-05-21 12:00 UTC [TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY](https://www.quantisnow.com/insight/tyra-biosciences-and-bcan-establish-may-21-as-upper-tract-6566450)
- 2026-05-19 12:32 UTC [Analyst Coverage Initiated] [Wolfe Research initiated coverage on Tyra Biosciences](https://www.quantisnow.com/insight/wolfe-research-initiated-coverage-on-tyra-biosciences-6561862)
- 2026-05-15 20:19 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-tyra-biosciences-inc-6557660)
- 2026-05-15 16:50 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-tyra-biosciences-inc-6556620)
- 2026-05-14 20:56 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-tyra-biosciences-inc-6554632)
- 2026-05-13 12:03 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Tyra Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-tyra-biosciences-inc-6549804)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/TYRA
- Earnings history: https://www.quantisnow.com/earnings/TYRA
- Dividend history: https://www.quantisnow.com/dividends/TYRA
- Insider transactions: https://www.quantisnow.com/insiders/TYRA
- Options chain: https://www.quantisnow.com/options/TYRA
- SEC 8-K filings only: https://www.quantisnow.com/company/TYRA/8-k
- RSS and alerts for TYRA: https://www.quantisnow.com/docs/rss-feeds.md